All In Biotech

Drug Trial Radar · NCT03827798

Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa

A Randomized, Subject and Investigator Blinded, Placebo-controlled and Multi-center Platform Study, to Assess Efficacy and Safety of Different Investigational Drugs in Patients With Moderate to Severe Hidradenitis Suppurativa

Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 248 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

248

Actual

Start

Feb 27, 2019

Primary completion

Dec 4, 2024

Study completion Sep 11, 2026

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Feb 1, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to assess preliminary efficacy and safety of CFZ533/iscalimab (Cohort A), LYS006 (Cohort B), MAS825 (Cohort C), LOU064/remibrutinib (Cohort D) and VAY736/ianalumab (Cohort E) in patients with moderate to severe hidradenitis suppurativa and to determine if CFZ533, LYS006, MAS825, LOU064 and VAY736 have an adequate clinical profile for further clinical development.

Conditions

  • Hidradenitis Suppurativa

Interventions

  • CFZ533Drug

    CFZ533 600 mg administered subcutaneous (s.c) weekly for 4 weeks, followed by bi-weekly until Week 15.

  • Placebo to CFZ533Drug

    Placebo administered subcutaneous (s.c) weekly for 4 weeks, followed by bi-weekly until Week 15.

  • LYS006Drug

    LYS006 20 mg administered orally twice per day until Week 16.

  • Placebo to LYS006Drug

    Placebo administered orally twice per day until Week 16.

  • MAS825Drug

    MAS825 300 mg administered s.c. bi-weekly for 4 weeks, followed by monthly until Week 13.

  • Placebo to MAS825Drug

    Placebo administered s.c. bi-weekly for 4 weeks, followed by monthly until Week 13.

  • LOU064 25mgDrug

    LOU064 25 mg administered orally twice per day until Week 16.

  • LOU064 100mgDrug

    LOU064 100 mg administered orally twice per day until Week 16.

  • Placebo to LOU064Drug

    Placebo administered orally twice per day until Week 16.

  • VAY736Drug

    VAY736 300 mg administered s.c every 4 weeks until Week 13.

  • Placebo to VAY736Drug

    Placebo administered s.c every 4 weeks until Week 13.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving Clinical Response Measured by Simplified Hidradenitis Suppurativa (sHiSCR)Time frame: Baseline, Week 16

Locations

36 sites in 11 countries. Site status is shown where the registry gives one.

  • Olympian Clinical Research

    Clearwater, Florida

  • Park Avenue Dermatology PA

    Orange Park, Florida

  • University Of South Florida

    Tampa, Florida

  • Advanced Medical Research

    Sandy Springs, Georgia

  • NorthShore University Health System

    Evanston, Illinois

  • Dawes Fretzin Clinical Rea Group

    Indianapolis, Indiana

  • Penn State Milton S Hershey Medical Center

    Hershey, Pennsylvania

  • Medical University of South Carolina MUSC

    Charleston, South Carolina

  • Novartis Investigative Site

    Graz, Austria

  • Novartis Investigative Site

    Brussels, Belgium

  • Novartis Investigative Site

    Prague, Czechia

  • Novartis Investigative Site

    Copenhagen, Denmark

  • Novartis Investigative Site

    Roskilde, Denmark

  • Novartis Investigative Site

    Antony, France

  • Novartis Investigative Site

    Lyon, France

  • Novartis Investigative Site

    Marseille, France

  • Novartis Investigative Site

    Nice, France

  • Novartis Investigative Site

    Reims, France

  • Novartis Investigative Site

    Rouen, France

  • Novartis Investigative Site

    Bochum, Germany

  • Novartis Investigative Site

    Hamburg, Germany

  • Novartis Investigative Site

    Schwerin, Germany

  • Novartis Investigative Site

    Frankfurt, Germany, Germany

  • Novartis Investigative Site

    Budapest, Hungary

  • Novartis Investigative Site

    Szeged, Hungary

  • Novartis Investigative Site

    Pécs, Baranya, Hungary

  • Novartis Investigative Site

    Debrecen, Hajdu Bihar Megye, Hungary

  • Novartis Investigative Site

    Kopavogur, Iceland

  • Novartis Investigative Site

    Groningen, Provincie Groningen, Netherlands

  • Novartis Investigative Site

    Rotterdam, South Holland, Netherlands

  • Novartis Investigative Site

    Barcelona, Spain

  • Novartis Investigative Site

    Las Palmas GC, Spain

  • Novartis Investigative Site

    Valencia, Spain

  • Novartis Investigative Site

    Granada, Andalusia, Spain

  • Novartis Investigative Site

    Sabadell, Barcelona, Spain

  • Novartis Investigative Site

    Manises, Valencia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.